The Let-7 microRNA precursor gives rise to let-7, a microRNA (miRNA) involved in control of stem-cell division and differentiation.[1]let-7, short for "lethal-7", was discovered along with the miRNA lin-4 in a study of developmental timing in C. elegans,[2] making these miRNAs the first ever discovered. let-7 was later identified in humans as the first human miRNA , and is highly conserved across many species.[3][4] Dysregulation of let-7 contributes to cancer development in humans by preventing differentiation of cells, leaving them stuck in a stem-cell like state.[1]let-7 is therefore classified as a tumor suppressor.
The let-7 microRNA family refers to the many slight variations of let-7 that exist both within a single organism and across species. In humans, for example, there are ten unique let-7 family member sequences: let-7a through g, let-7i, mir-98, and mir-202.[1]
In humans, mature let-7 acts via RNA-induced silencing by complexing with RISC and binding to target mRNA, preventing translation into protein. Known targets of let-7 include proteins related to the cell cycle and proliferation, such as MYC, RAS, cyclin D, HMGA2, and CDC25A.[1] Knockdown of these proteins by let-7 prevents proliferation and induces differentiation of cells. Important inhibitors of let-7 include LIN28, which binds to let-7 directly,[5] and the proto-oncogene MYC, which suppresses expression.[6]
Genomic Locations
In human genome, the cluster let-7a-1/let-7f-1/let-7d is inside the region B at 9q22.3, with the defining marker D9S280-D9S1809. One minimal LOH (loss of heterozygosity) region, between loci D11S1345-D11S1316, contains the cluster miR-125b1/let-7a-2/miR-100. The cluster miR-99a/let-7c/miR-125b-2 is in a 21p11.1 region of HD (homozygous deletions). The cluster let-7g/miR-135-1 is in region 3 at 3p21.1-p21.2.[7]
The let-7 family
The lethal-7 (let-7) gene was first discovered in the nematode C. elegans as a key developmental regulator and became one of the first two known microRNAs (the other one is lin-4).[8] Soon, let-7 was found in the fruit fly (Drosophila), and identified as the first known human miRNA by a BLAST (basic local alignment search tool) research.[9] The mature form of let-7 family members is highly conserved across species.
In C. elegans
In C. elegans, the let-7 family consists of genes encoding nine miRNAs sharing the same seed sequence.[10] Among them, let-7, mir-84, mir-48 and mir-241 are involved in the C. elegansheterochronic pathway, sequentially controlling developmental timing of larva transitions.[11] Most animals with loss-of-function let-7 mutation burst through their vulvas and die, and therefore the mutant is lethal (let).[8] The mutants of other let-7 family members have a radio-resistant phenotype in vulval cells, which may be related to their ability to repress RAS.[12]
In Drosophila
There is only one single let-7 gene in the Drosophila genome, which has the identical mature sequence to the one in C. elegans.[13] The role of let-7 has been demonstrated in regulating the timing of neuromuscular junction formation in the abdomen and cell-cycle in the wing.[14] Furthermore, the expression of pri-, pre- and mature let-7 have the same rhythmic pattern with the hormone pulse before each cuticular molt in Drosophila.[15]
In vertebrates
The let-7 family has a lot more members in vertebrates than in C. elegans and Drosophila.[13] The sequences, expression timing, as well as genomic clustering of these miRNAs members are all conserved across species.[16] The direct role of let-7 family in vertebrate development has not been clearly shown as in less complex organisms, yet the expression pattern of let-7 family is indeed temporally regulated during developmental processes.[17] Functionally, let-7 has been shown in early vertebrates to control the differentiation of mesoderm and ectoderm.[18] Given that the expression levels of let-7 members are significantly low in human cancers and cancer stem cells,[19] the major function of let-7 genes may be to promote terminal differentiation in development and tumor suppression.
Regulation of expression
Although the levels of mature let-7 members are undetectable in undifferentiated cells, the primary transcripts and the hairpin precursors of let-7 are present in these cells.[20] It indicates that the mature let-7 miRNAs may be regulated in a post-transcriptional manner.
By pluripotency promoting factor LIN28
As one of the genes involved in (but not essential for) induced pluripotent stem (iPS) cell reprogramming,[21]LIN28 expression is reciprocal to that of mature let-7.[5] LIN28 selectively binds the primary and precursor forms of let-7, and inhibits the processing of pri-let-7 to form the hairpin precursor.[22] This binding is facilitated by the conserved loop sequence of primary let-7 family members and RNA-binding domains of LIN28 proteins.[23] Lin-28 uses two zinc knuckle domains to recognize the NGNNG motif in the let-7 precursors,[24] while the Cold-shock domain, connected by a flexible linker, binds to a closed loop in the precursors.[25] On the other hand, let-7 miRNAs in mammals have been shown to regulate LIN28,[26] which implies that let-7 might enhance its own level by repressing LIN28, its negative regulator.[27]
In autoregulatory loop with MYC
Expression of let-7 members is controlled by MYC binding to their promoters. The levels of let-7 have been reported to decrease in models of MYC-mediated tumorigenesis, and to increase when MYC is inhibited by chemicals.[6] In a twist, there are let-7-binding sites in MYC 3' untranslated region(UTR) according to bioinformatic analysis, and let-7 overexpression in cell culture decreased MYC mRNA levels.[28] Therefore, there is a double-negative feedback loop between MYC and let-7. Furthermore, let-7 could lead to IMP1 (insulin-like growth factor II mRNA-binding protein) depletion, which destabilizes MYC mRNA, thus forming an indirect regulatory pathway.[29]
Targets of let-7
Oncogenes: RAS, HMGA2
Let-7 has been demonstrated to be a direct regulator of RAS expression in human cells[30] All the three RAS genes in human, K-, N-, and H-, have the predicted let-7 binding sequences in their 3'UTRs. In lung cancer patient samples, expression of RAS and let-7 showed reciprocal pattern, which has low let-7 and high RAS in cancerous cells, and high let-7 and low RAS in normal cells. Another oncogene, high mobility group A2 (HMGA2), has also been identified as a target of let-7. Let-7 directly inhibits HMGA2 by binding to its 3'UTR.[31] Removal of let-7 binding site by 3'UTR deletion cause overexpression of HMGA2 and formation of tumor.
Cell cycle, proliferation, and apoptosis regulators
Let-7 has been implicated in post-transcriptional control of innate immune responses to pathogenic agents. Macrophages stimulated with live bacteria or purified microbial components down-regulate the expression of several members of the let-7 microRNA family to relieve repression of immune-modulatory cytokines IL-6 and IL-10.[34][35]Let-7 has also been implicated in the negative regulation of TLR4, the major immune receptor of microbial lipopolysaccharide and down-regulation of let-7 both upon microbial and protozoan infection might elevate TLR4 signaling and expression.[36][37]Let-7 has furthermore been reported to regulate the production of cytokine IL-13 by T lymphocytes during allergic airway inflammation thus linking this microRNA to adaptive immunity as well.[38] Down-modulation of let-7 negative regulator Lin28b in human T lymphocytes is believed to accrue during early neonate development to reprogram the immune system towards defense.[39]
Potential clinical use in cancer
Given the prominent phenotype of cell overproliferation and dedifferentiation by let-7 loss-of-function in nematodes, and the role of its targets on cell destiny determination, let-7 is closely associated with human cancer and acts as a tumor suppressor.
Prognostic Biomarkers
Numerous reports have shown that the expression levels of let-7 are frequently low and the chromosomal clusters of let-7 are often deleted in many cancers.[7]Let-7 is expressed at higher levels in more differentiated tumors, which also have lower levels of activated oncogenes such as RAS and HMGA2. Therefore, expression levels of let-7 could be prognostic markers in several cancers associated with differentiation stages.[40] In lung cancer, for example, reduced expression of let-7 is significantly correlated with reduced postoperative survival.[41] The expression of let-7b and let-7g microRNAs are significantly associated with overall survival in 1262 breast cancer patients.[42]
Therapy
Let-7 is also a very attractive potential therapeutic that can prevent tumorigenesis and angiogenesis, typically in cancers that underexpress let-7.[43] Lung cancer, for instance, has several key oncogenic mutations including p53, RAS and MYC, some of which may directly correlate with the reduced expression of let-7, and may be repressed by introduction of let-7.[41]Intranasal administration of let-7 has already been found effective in reducing tumor growth in a transgenic mouse model of lung cancer.[44] Similar restoration of let-7 was also shown to inhibit cell proliferation in breast, colon and hepatic cancers, lymphoma, and uterine leiomyoma.[45]
^Esquela-Kerscher A, Slack FJ (April 2006). "Oncomirs - microRNAs with a role in cancer". Nature Reviews. Cancer. 6 (4): 259–269. doi:10.1038/nrc1840. PMID16557279. S2CID10620165.
^Kumar M, Ahmad T, Sharma A, Mabalirajan U, Kulshreshtha A, Agrawal A, Ghosh B (November 2011). "Let-7 microRNA-mediated regulation of IL-13 and allergic airway inflammation". The Journal of Allergy and Clinical Immunology. 128 (5): 1077–1085. doi:10.1016/j.jaci.2011.04.034. PMID21616524.
^Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L, Győrffy B (December 2016). "miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients". Breast Cancer Research and Treatment. 160 (3): 439–446. doi:10.1007/s10549-016-4013-7. PMID27744485. S2CID11165696.
Newman MA, Hammond SM (August 2010). "Lin-28: an early embryonic sentinel that blocks Let-7 biogenesis". The International Journal of Biochemistry & Cell Biology. 42 (8): 1330–1333. doi:10.1016/j.biocel.2009.02.023. PMID20619222.
Lee ST, Chu K, Oh HJ, Im WS, Lim JY, Kim SK, et al. (March 2011). "Let-7 microRNA inhibits the proliferation of human glioblastoma cells". Journal of Neuro-Oncology. 102 (1): 19–24. doi:10.1007/s11060-010-0286-6. PMID20607356. S2CID29835621.
Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR, Xiao GG (May 2011). "Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer". Breast Cancer Research and Treatment. 127 (1): 69–80. doi:10.1007/s10549-010-0972-2. PMID20535543. S2CID29668405.
Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, et al. (May 2010). "The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma". Journal of Hepatology. 52 (5): 698–704. doi:10.1016/j.jhep.2009.12.024. PMID20347499.
Klemke M, Meyer A, Hashemi Nezhad M, Belge G, Bartnitzke S, Bullerdiek J (January 2010). "Loss of let-7 binding sites resulting from truncations of the 3' untranslated region of HMGA2 mRNA in uterine leiomyomas". Cancer Genetics and Cytogenetics. 196 (2): 119–123. doi:10.1016/j.cancergencyto.2009.09.021. PMID20082846.
Oh JS, Kim JJ, Byun JY, Kim IA (January 2010). "Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras". International Journal of Radiation Oncology, Biology, Physics. 76 (1): 5–8. doi:10.1016/j.ijrobp.2009.08.028. PMID20005451.
Mu G, Liu H, Zhou F, Xu X, Jiang H, Wang Y, Qu Y (April 2010). "Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas". Human Pathology. 41 (4): 493–502. doi:10.1016/j.humpath.2009.08.022. PMID20004941.
Rybak A, Fuchs H, Hadian K, Smirnova L, Wulczyn EA, Michel G, et al. (December 2009). "The let-7 target gene mouse lin-41 is a stem cell specific E3 ubiquitin ligase for the miRNA pathway protein Ago2". Nature Cell Biology. 11 (12): 1411–1420. doi:10.1038/ncb1987. PMID19898466. S2CID10902783.
Wang X, Hulshizer RL, Erickson-Johnson MR, Flynn HC, Jenkins RB, Lloyd RV, Oliveira AM (August 2009). "Identification of novel HMGA2 fusion sequences in lipoma: evidence that deletion of let-7 miRNA consensus binding site 1 in the HMGA2 3' UTR is not critical for HMGA2 transcriptional upregulation". Genes, Chromosomes & Cancer. 48 (8): 673–678. doi:10.1002/gcc.20674. PMID19431195. S2CID5328884.
Torrisani J, Bournet B, du Rieu MC, Bouisson M, Souque A, Escourrou J, et al. (August 2009). "let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression". Human Gene Therapy. 20 (8): 831–844. doi:10.1089/hum.2008.134. PMID19323605.
Büssing I, Slack FJ, Grosshans H (September 2008). "let-7 microRNAs in development, stem cells and cancer". Trends in Molecular Medicine. 14 (9): 400–409. doi:10.1016/j.molmed.2008.07.001. PMID18674967.
Garfield D (May 2008). "let-7 microRNA expression and the distinction between nonmucinous and mucinous bronchioloalveolar carcinomas". Lung Cancer. 60 (2): 307. doi:10.1016/j.lungcan.2008.02.010. PMID18395292.
Inamura K, Togashi Y, Nomura K, Ninomiya H, Hiramatsu M, Satoh Y, et al. (December 2007). "let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis". Lung Cancer. 58 (3): 392–396. doi:10.1016/j.lungcan.2007.07.013. PMID17728006.
Pasquinelli AE, McCoy A, Jiménez E, Saló E, Ruvkun G, Martindale MQ, Baguñà J (2003). "Expression of the 22 nucleotide let-7 heterochronic RNA throughout the Metazoa: a role in life history evolution?". Evolution & Development. 5 (4): 372–378. doi:10.1046/j.1525-142X.2003.03044.x. PMID12823453. S2CID32723915.